Stocks and Investing
Stocks and Investing
Fri, December 11, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, December 10, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Raghuram Selvaraju Maintained (BBIO) at Strong Buy with Increased Target to $64 on, Dec 10th, 2020
Raghuram Selvaraju of HC Wainwright & Co., Maintained "BridgeBio Pharma, Inc." (BBIO) at Strong Buy with Increased Target from $53 to $64 on, Dec 10th, 2020.
Raghuram has made no other calls on BBIO in the last 4 months.
There is 1 other peer that has a rating on BBIO. Out of the 1 peers that are also analyzing BBIO, 0 agree with Raghuram's Rating of Hold.
This is the rating of the analyst that currently disagrees with Raghuram
- Mani Foroohar of "SVB Leerink" Maintained at Buy with Increased Target to $44 on, Friday, December 4th, 2020
Contributing Sources